So far, 2019 has been a transformative year for Kitov Pharmaceuticals (KTOV) and its shareholders. The company has inked its U.S. commercialization partnership with Coeptis Pharmaceuticals for its lead product Consensi, which the company expects to launch at some point this year. Now, the company focused its efforts on transmuting into an oncology intensive company by progressing its TyrNovo oncology candidate NT-219. Kitov planned to submit an IND for NT-219 early this year, but it appears the management has been hard at work negotiating the acquisition of FameWave and securing the funding from